
The ATTEST-2 trial compared tenecteplase and alteplase for thrombolysis in acute ischaemic stroke. Involving 1,777 patients, it found tenecteplase 0.25 mg/kg was non-inferior to alteplase 0.9 mg/kg in achieving better outcomes at 90 days. While tenecteplase did not show superiority, its simpler administration could facilitate treatment, especially during interhospital transfers. These findings suggest tenecteplase should be preferred for acute ischaemic stroke thrombolysis.
Like
Save
Share